Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy

Brachytherapy

Volumn 10, Issue 4, 2011, Pages 261-268

  Carpenter, Todd J ^a   Forsythe, Kevin ^a   Kao, Johnny ^a   Stone, Nelson N ^a   Stock, Richard G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Locally advanced; Prostate cancer; T3

Indexed keywords

ANTIANDROGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; EXTRAPROSTATIC PROSTATE CANCER; FOLLOW UP; GLEASON SCORE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; FOLLOW-UP STUDIES; HORMONES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958786491     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2010.10.002     Document Type: Article

References (48)

1. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766-771.
2. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
3. Kattan M.W., Zelefsky M.J., Kupelian P.A., et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000, 18:3352-3359.
4. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999, 17:168-172.
5. Epstein J.I., Partin A.W., Potter S.R., et al. Adenocarcinoma of the prostate invading the seminal vesicle: Prognostic stratification based on pathologic parameters. Urology 2000, 56:283-288.
6. Blute M.L., Bergstralh E.J., Iocca A., et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001, 165:119-125.
7. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 1999, 281:1598-1604.
8. Zietman A.L., Edelstein R.A., Coen J.J., et al. Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994, 43:828-833.
9. Kupelian P.A., Buchsbaum J.C., Elshaikh M., et al. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer 2002, 95:2302-2307.
10. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993, 71:3582-3593.
11. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50:1243-1252.
12. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
13. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002, 360:103-106.
14. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21:3972-3978.
15. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199.
16. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578.
17. Swanson G.P., Hussey M.A., Tangen C.M., et al. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007, 25:2225-2229.
18. D'Amico A.V., Moran B.J., Braccioforte M.H., et al. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009, 27:3923-3928.
19. Stock R.G., Cahlon O., Cesaretti J.A., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59:1352-1359.
20. Merrick G.S., Butler W.M., Wallner K.E., et al. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 2007, 68:34-40.
21. Stock R.G., Cesaretti J.A., Hall S.J., et al. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009, 104:1631-1636.
22. Copp H., Bissonette E.A., Theodorescu D. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. Urology 2005, 65:1146-1151.
23. Coblentz T.R., Bissonette E.A., Williams K.R., et al. Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients. Prostate Cancer Prostatic Dis 2002, 5:219-225.
24. Ward J.F., Slezak J.M., Blute M.L., et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005, 95:751-756.
25. Loeb S., Smith N.D., Roehl K.A., et al. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007, 69:1170-1175.
26. Ho A.Y., Burri R.J., Jennings G.T., et al. Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer. Brachytherapy 2007, 6:38-43.
27. Greene F.L., Page D.L., Fleming I.D., et al. AJCC Cancer Staging Manual 2002, Springer-Verlag, New York, NY.
28. Stock R.G., Stone N.N., Ianuzzi C., et al. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: Implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys 1995, 33:815-821.
29. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995, 32:219-225.
30. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006, 64:527-533.
31. Roach M., DeSilvio M., Valicenti R., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
32. Nrusis M. SPSS 10.0 guide to data analysis 2000, Prentice Hall, Upper Saddle River, NJ.
33. Fuks Z., Leibel S.A., Wallner K.E., et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 1991, 21:537-547.
34. Zagars G.K., von Eschenbach A.C., Ayala A.G., et al. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 1991, 68:2370-2377.
35. Gerber G.S., Thisted R.A., Chodak G.W., et al. Results of radical prostatectomy in men with locally advanced prostate cancer: A multi-institutional pooled analysis. Eur Urol 1997, 32:385-390.
36. Swindle P., Eastham J.A., Ohori M., et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2008, 179:S47-S51.
37. Masterson T.A., Pettus J.A., Middleton R.G., et al. Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: Prognostic stratification of pt3b disease by nodal and margin status. Urology 2005, 66:152-155.
38. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005, 294:1233-1239.
39. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
40. Stone N.N., Stock R.G., Cesaretti J.A., et al. Local control following permanent prostate brachytherapy: Effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 2010, 76:355-360.
41. Zelefsky M.J., Yamada Y., Kollmeier M.A., et al. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008, 53:1172-1179.
42. Liauw S.L., Stadler W.M., Correa D., et al. Dose-escalated radiotherapy for high-risk prostate cancer: Outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2009, 77:125-130.
43. Zapatero A., Valcarcel F., Calvo F., et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 2005, 23:6561-6568.
44. Chiang P.H., Fang F.M., Jong W.C., et al. High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation. Int J Urol 2004, 11:152-158.
45. Martin T., Roddiger S., Kurek R., et al. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 2004, 71:35-41.
46. Davis B.J., Pisansky T.M., Wilson T.M., et al. The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy. Cancer 1999, 85:2630-2637.
47. Shipley W.U., Verhey L.J., Munzenrider J.E., et al. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995, 32:3-12.
48. Martinez A.A., Gustafson M.D., Gonzalez J., et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcomes in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002, 53:316-327.